Cargando…

Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is one of the most effective therapeutic options for the treatment of metastatic, well-differentiated neuroendocrine tumors (NETs). It improves progressive disease-free survival and enables the control of hormone secretion in functioning tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Opalińska, Marta, Morawiec-Sławek, Karolina, Kania-Kuc, Adrian, Al Maraih, Ibraheem, Sowa-Staszczak, Anna, Hubalewska-Dydejczyk, Alicja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420847/ https://www.ncbi.nlm.nih.gov/pubmed/36046793 http://dx.doi.org/10.3389/fendo.2022.929391

Ejemplares similares

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

[(68)Ga]Ga-DOTA-TATE uptake due to COVID-19 vaccination
por: Weiler-Sagie, Michal, et al.
Publicado: (2021)

Physiological Biodistribution of (68)Ga-DOTA-TATE in Normal Subjects
por: Özgüven, Salih, et al.
Publicado: (2021)

PET-CT imaging of pulmonary inflammation using [(68)Ga]Ga-DOTA-TATE
por: Puuvuori, Emmi, et al.
Publicado: (2022)

Application of (68)Ga-DOTA-TATE PET/CT in metastatic neuroendocrine tumor of gastrointestinal origin
por: Papadakis, Georgios Z., et al.
Publicado: (2017)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Standardized image quality for (68)Ga-DOTA-TATE PET/CT
por: Cox, Christina P. W., et al.
Publicado: (2020)

Correlations between [(68)Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [(177)Lu]Lu-DOTA-TATE
por: Bruvoll, Ragnar, et al.
Publicado: (2023)

The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors
por: Novruzov, Fuad, et al.
Publicado: (2021)

The Search for an Alternative to [(68)Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of (18)F-labeled Somatostatin Analog Development
por: Waldmann, Christopher M., et al.
Publicado: (2019)

Head-to-Head Comparison of (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 PET/CT in Patients With Tumor-Induced Osteomalacia: A Prospective Study
por: Hou, Guozhu, et al.
Publicado: (2022)

CYP3A4 inhibitors do not influence [(68)Ga]Ga-DOTA-TATE uptake in liver tissue
por: Chahid, Youssef, et al.
Publicado: (2023)

A false positive 68Ga-DOTA-TATE involvement in an adrenal mass: Kaposi Sarcoma
por: Ozbas, Burak, et al.
Publicado: (2023)

Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
por: Opalińska, Marta, et al.
Publicado: (2021)

SAT-575 Radiolabeled Somatostatin Receptor Analog (86)Y-EB-TATE is Characterized by Superior Tumor Uptake Compared to (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 in Thyroid Cancer Mice Models
por: Thakur, Shilpa, et al.
Publicado: (2019)

Al[(18)F]F-NOTA-Octreotide Is Comparable to [(68)Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population
por: Haeger, Arlette, et al.
Publicado: (2023)

The Impact of Total Variation Regularized Expectation Maximization Reconstruction on (68)Ga-DOTA-TATE PET/CT Images in Patients With Neuroendocrine Tumor
por: Liu, Lin, et al.
Publicado: (2022)

Postoperative [(68)Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1
por: Teske, Nico, et al.
Publicado: (2023)

Clinical Approach to Neuroendocrine Neoplasm Associated With Ovarian Teratoma
por: Opalińska, Marta, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of (68)Ga DOTA-TATE PET/CT, (111)In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors
por: Froelich, Matthias Frank, et al.
Publicado: (2021)

Personal dose equivalent H(p)(0.07) during (68)Ga-DOTA-TATE production procedures
por: Wrzesień, M., et al.
Publicado: (2023)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Self-Administration of Long-Acting Somatostatin Analogues in NET Patients—Does It Affect the Clinical Outcome?
por: Sowa-Staszczak, Anna, et al.
Publicado: (2021)

Results of a Prospective Trial to Compare (68)Ga-DOTA-TATE with SiPM-Based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors
por: Baratto, Lucia, et al.
Publicado: (2021)

SAT-618 Ectopic Thyroid-Stimulating Hormone-Secreting Pituitary Adenoma of the Nasopharynx Diagnosed by (68)Ga-DOTA-TATE PET/CT
por: Kim, Stephanie, et al.
Publicado: (2019)

Adventures in radiosynthesis of clinical grade [(68)Ga]Ga-DOTA-Siglec-9
por: Käkelä, Meeri, et al.
Publicado: (2018)

Preparation and Biological Study of (68)Ga-DOTA-alendronate
por: Fakhari, Ashraf, et al.
Publicado: (2016)

Comparative evaluation of (68)Ga-labelled TATEs: the impact of chelators on imaging
por: Xia, Yuxiao, et al.
Publicado: (2020)

Initial Clinical Experience with (68)Ga-DOTA-NOC Prepared Using (68)Ga from Nanoceria-polyacrylonitrile Composite Sorbent-based (68)Ge/(68)Ga Generator and Freeze-dried DOTA-NOC Kits
por: Chandra, Piyush, et al.
Publicado: (2017)

Additional Value of [18F]FDG PET/CT in Detection of Suspected Malignancy in Patients with Paraneoplastic Neurological Syndromes Having Negative Results of Conventional Radiological Imaging
por: Opalińska, Marta, et al.
Publicado: (2022)

Occupational radiation exposure assessment during the management of [(68)Ga]Ga-DOTA-TOC
por: Riveira-Martin, Mercedes, et al.
Publicado: (2022)

Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [(177)Lu]Lu-DOTA-TATE or [(177)Lu]Lu-DOTA-TATE and [(90)Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
por: Durma, Adam Daniel, et al.
Publicado: (2023)

Relevance of Volumetric Parameters Applied to [(68)Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT
por: Urso, Luca, et al.
Publicado: (2023)

Diagnostic performance and impact on patient management of [(68)Ga]Ga-DOTA-TOC PET/CT in colorectal neuroendocrine tumors derived from hindgut
por: Delabie, Pierre, et al.
Publicado: (2022)

Comment on: Somatostatin receptor SPECT
por: Hubalewska-Dydejczyk, Alicja, et al.
Publicado: (2012)

Kinetic Modelling of [(68)Ga]Ga-DOTA-Siglec-9 in Porcine Osteomyelitis and Soft Tissue Infections
por: Jødal, Lars, et al.
Publicado: (2019)

Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG Uptake in Esophageal Cancer
por: Liu, Huipan, et al.
Publicado: (2022)

Impact of segmentation and discretization on radiomic features in (68)Ga-DOTA-TOC PET/CT images of neuroendocrine tumor
por: Liberini, Virginia, et al.
Publicado: (2021)

Preparation and Evaluation of [(18)F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [(68)Ga]Ga-DOTA/NOTA-NOC
por: Dam, Johan Hygum, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s41kdktfl5pgoh11aslm18e54g